STAT

Why do biopharma’s elites make the annual pilgrimage to Davos?

A who’s-who list of pharma royalty is headed to the Swiss ski resort town of Davos for four days of hobnobbing with politicians, CEOs, and one-percenters from around the globe.
Source: FABRICE COFFRINI/AFP/Getty Images

A who’s-who list of biopharma royalty is headed to the Swiss ski resort town of Davos for four days of hobnobbing this week with politicians, CEOs, and one-percenters from around the globe.

There will be big names like Pfizer’s COO Albert Bourla, Novartis’s incoming CEO Vasant Narasimhan, Roche Chairman Christoph Franz, Illumina’s executive chairman Jay Flatley, and Medtronic’s CEO Omar Ishrak. FDA Commissioner Scott Gottlieb will be there, as will the director of the National Institutes of Health, Francis Collins.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks